hERG epitope mimic-decoy peptide corrects autoimmune-long QT syndrome in guinea pigs
Treatment with MDP4 results in recovery of both the QT-interval prolongation in vivo and I<sub>Kr</sub> inhibition in vitro. MDP4 and other conceptually similar molecules may represent an innovative therapeutic approach for autoimmune LQTS in humans, and, prospectively, for other forms of arrhythmogenic autoimmune cardiac channelopathies.
Authors
- Jean‐Baptiste Reisqs (ORCID: https://orcid.org/0000-0001-9881-6670)
- Riccardo Accioli (ORCID: https://orcid.org/0000-0003-1983-4040)
- Vamsi Krishna Murthy Ginjupalli (ORCID: https://orcid.org/0000-0002-5022-1683)
- Pietro Enea Lazzerini (ORCID: https://orcid.org/0000-0001-6721-1214)
- Timothy Cardozo (ORCID: https://orcid.org/0000-0002-0643-4497)
- Yvonne Sleiman (ORCID: https://orcid.org/0000-0002-1550-8945)
- Michael Cupelli (ORCID: https://orcid.org/0000-0001-8985-2290)
- Mohamed Boutjdir
- Manuel Becerra-Flores
Institutions
- University of Siena (IT)
- SUNY Downstate Health Sciences University (US)
- VA NY Harbor Healthcare System (US)
- Azienda Ospedaliera Universitaria Senese (IT)
- New York University (US)
Publication Details
- Journal
- Communications Medicine
- Published
- 2026-03-11
- DOI
- https://doi.org/10.1038/s43856-026-01508-7
- Primary Topic
- Viral Infections and Immunology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- U.S. Department of Veterans Affairs
- Office of Research and Development
- National Heart, Lung, and Blood Institute